NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is ...
INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...
Approval was supported by data from a randomized, intra-patient controlled trial, which included patients with confirmed invasive breast cancer, ductal carcinoma in situ, or both. The Food and Drug ...
(StatePoint) One in eight U.S. women will be diagnosed with breast cancer during their lifetime, and many of these patients will undergo a lumpectomy — a surgical treatment to remove the tumor while ...
Many women with two or three breast tumors can get by with lumpectomy surgery instead of having their whole breast removed, a new study suggests. In recent years, more patients with multiple tumors ...
Many women with two or three breast tumors can get by with lumpectomy surgery instead of having their whole breast removed, a new study suggests. In recent years, more patients with multiple tumors ...
DEAR MAYO CLINIC: I understand surgery is often included as part of the treatment plan for breast cancer. If I'm a candidate for lumpectomy but am also considering a mastectomy, what are some things I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback